In this video, health care analyst David Williamson discusses the recent events around Orexigen Therapeutics, including today's rarely seen price-increasing dilutive offering. Is Orexigen a looming threat to obesity-drug-making heavyweights Arena and VIVUS? Watch and find out.Â
A rare positive dilution.
David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
2 Artificial Intelligence (AI) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential
This Ultra-High-Yield Dividend Stock's Prognosis Is Improving
Why Medical Properties Trust Stock Popped Today
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
650%
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.